Download PDF
Digestive Disease Interventions 2017; 01(04): 259-264
DOI: 10.1055/s-0037-1621701
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA

Refractory Ascites: Treatment and Complications Utilizing Peritoneovenous (Denver) Shunt

Parvaneh Shadkam-Farrokhi
1   Division of Interventional Radiology, Department of Radiology, UCLA Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California
,
Edward Wolfgang Lee
1   Division of Interventional Radiology, Department of Radiology, UCLA Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California
2   UCLA Medical Center, UCLA Pfleger Liver Institute, Los Angeles, California
› Author Affiliations
Further Information

Publication History

03 December 2017

07 December 2017

Publication Date:
19 January 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Intractable ascites has long been an antagonizing problem for patients and medical providers. It is debilitating and frequently cannot be prevented by standard medical therapy. Ascites is primarily managed with salt restrictions, diuretics, and repeated paracentesis for symptomatic relief. However, 10% of patients become refractory to this first line of treatment. Several surgical methods such as the insertion of peritoneovenous shunts and transjugular intrahepatic portosystemic shunts have become popularized treatment modalities for the control of refractory ascites. Nevertheless, controversy resides over what is the best treatment method for the improvement in patients' quality of life and survival rate. We herein explore the different medical and surgical methods available for the control of refractory ascites with a focus on the advantages and complications associated with the usage of Denver peritoneovenous shunts.

Keywords

Denver shunt - peritoneovenous shunt - TIPS - complications

Note

The first author, Parvaneh Shadkam-Farrokhi is a trainee of Dr. Edward W. Lee.


 

  • References

  • 1 Forns X, Ginès A, Ginès P, Arroyo V. Management of ascites and renal failure in cirrhosis. Semin Liver Dis 1994; 14 (01) 82-96
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Yarmohammadi H. Denver Shunts vs TIPS for Ascites. Conference Presented: Global Embolization Cancer Symposium Technologies (GEST); May 5 2016; New York, NY
    PubMedGoogle Scholar
  • 3 Won JY, Choi SY, Ko H-K. , et al. Percutaneous peritoneovenous shunt for treatment of refractory ascites. J Vasc Interv Radiol 2008; 19 (12) 1717-1722
    CrossrefPubMedGoogle Scholar
  • 4 McIntyre N, Burroughs AK. Cirrhosis, Portal hypertension, and Ascites. In: Weatherall DJ, Ledingham JGG, Warrell DA. (eds). Oxford Textbook of Medicine 3rd Edition. Oxford University Press; 1996: 2085-100
    Google Scholar
  • 5 Arroyo V, Ginès P, Gerbes AL. , et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23 (01) 164-176
    CrossrefPubMedGoogle Scholar
  • 6 Salerno F, Guevara M, Bernardi M. , et al. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int 2010; 30 (07) 937-947
    CrossrefPubMedGoogle Scholar
  • 7 Ginès P, Cárdenas A, Arroyo V, Rodés J. Management of cirrhosis and ascites. N Engl J Med 2004; 350 (16) 1646-1654
    CrossrefPubMedGoogle Scholar
  • 8 Bhogal H, Sanyal AJ. Treatment of refractory ascites. Clin Liver Dis 2013; 2 (03) 140-142
    CrossrefPubMedGoogle Scholar
  • 9 Follo A, Llovet JM, Navasa M. , et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20 (06) 1495-1501
    CrossrefPubMedGoogle Scholar
  • 10 Guardiola J, Xiol X, Escribá JM. , et al. Prognosis assessment of cirrhotic patients with refractory ascites treated with a peritoneovenous shunt. Am J Gastroenterol 1995; 90 (12) 2097-2102
    PubMedGoogle Scholar
  • 11 Sooriakumaran P, McAndrew HF, Kiely EM, Spitz L, Pierro A. Peritoneovenous shunting is an effective treatment for intractable ascites. Postgrad Med J 2005; 81 (954) 259-261
    CrossrefPubMedGoogle Scholar
  • 12 Zervos EE, Rosemurgy AS. Management of medically refractory ascites. Am J Surg 2001; 181 (03) 256-264
    CrossrefPubMedGoogle Scholar
  • 13 Salerno F, Cammà C, Enea M, Rössle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007; 133 (03) 825-834
    CrossrefPubMedGoogle Scholar
  • 14 Rossle M, Haag K, Blum U. , et al. TIPS: Technical and early clinical complications. Hepatology 1993; 18: 103A
    PubMedGoogle Scholar
  • 15 Leveen HHCG, Christoudias G, Ip M, Luft R, Falk G, Grosberg S. Peritoneo-venous shunting for ascites. Ann Surg 1974; 180 (04) 580-591
    CrossrefPubMedGoogle Scholar
  • 16 Martin LG. Percutaneous placement and management of peritoneovenous shunts. Semin Intervent Radiol 2012; 29 (02) 129-134
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Kirsch WM, Newkirk JB, Predecki PK. Clinical experience with the Denver shunt: a new silicone-rubber shunting device for the treatment of hydrocephalus. Technical note. J Neurosurg 1970; 32 (02) 258-264
    CrossrefPubMedGoogle Scholar
  • 18 Lund RHMM, Moritz MW. Complications of Denver peritoneovenous shunting. Arch Surg 1982; 117 (07) 924-928
    CrossrefPubMedGoogle Scholar
  • 19 Stukan M. Drainage of malignant ascites: patient selection and perspectives. Cancer Management and Research 2017; 9: 115-130 doi:10.2147/cmar.s100210
    CrossrefPubMedGoogle Scholar
  • 20 Lerner RGNJ, Nelson JC, Corines P, del Guercio LR. Disseminated intravascular coagulation. Complication of LeVeen peritoneovenous shunts. JAMA 1978; 240 (19) 2064-2066
    CrossrefPubMedGoogle Scholar
  • 21 Agarwal S, Joyner Jr KA, Swaim MW. Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease. Am J Gastroenterol 2000; 95 (11) 3218-3224
    CrossrefPubMedGoogle Scholar
  • 22 Gleysteen JJHC, Hussey CV, Heckman MG. The cause of coagulopathy after peritoneovenous shunt for malignant ascites. Arch Surg 1990; 125 (04) 474-477
    CrossrefPubMedGoogle Scholar
  • 23 Baele G, Rasquin K, Barbier F. Coagulant, fibrinolytic, and aggregating activity in ascitic fluid. Am J Gastroenterol 1986; 81 (06) 440-443
    PubMedGoogle Scholar
  • 24 Schölmerich J, Zimmermann U, Köttgen E. , et al. Proteases and antiproteases related to the coagulation system in plasma and ascites. Prediction of coagulation disorder in ascites retransfusion. J Hepatol 1988; 6: 359-363
    CrossrefPubMedGoogle Scholar
  • 25 Bick RL. Disseminated intravascular coagulation: a review of etiology, pathophysiology, diagnosis, and management: guidelines for care. Clinical and Applied Thrombosis/Hemostasis 2002; 8 (01) 1-31 doi:10.1177/107602960200800103
    CrossrefPubMedGoogle Scholar
  • 26 Harmon DC, Demirjian Z, Ellman L, Fischer JE. Disseminated intravascular coagulation with the peritoneovenous shunt. Ann Intern Med 1979; 90 (05) 774-776
    CrossrefPubMedGoogle Scholar
  • 27 Fulenwider Sr JT, Smith III RB, Redd SC. , et al. Peritoneovenous shunts. Lessons learned from an eight-year experience with 70 patients. Arch Surg 1984; 119 (10) 1133-1137
    CrossrefPubMedGoogle Scholar
  • 28 Smith EMJG, Jayson GC. The current and future management of malignant ascites. Clin Oncol (R Coll Radiol) 2003; 15 (02) 59-72
    CrossrefPubMedGoogle Scholar
  • 29 Hussain FFMZ, Meer ZF, Lopez AJ. Peritoneovenous shunt insertion for intractable ascites: a district general hospital experience. Cardiovasc Intervent Radiol 2004; 27 (04) 325-328
    PubMedGoogle Scholar
  • 30 Rodés J. Pathogenesis and treatment of ascites. J Intern Med 1996; 240 (03) 111-114
    CrossrefPubMedGoogle Scholar
  • 31 Tomiyama K, Takahashi M, Fujii T. , et al. Improved quality of life for malignant ascites patients by Denver peritoneovenous shunts. Anticancer Res 2006; 26 (3B): 2393-2395
    PubMedGoogle Scholar
  • 32 Seike M, Maetani I, Sakai Y. Treatment of malignant ascites in patients with advanced cancer: peritoneovenous shunt versus paracentesis. J Gastroenterol Hepatol 2007; 22 (12) 2161-2166
    CrossrefPubMedGoogle Scholar
  • 33 Ginès P, Uriz J, Calahorra B. , et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123 (06) 1839-1847
    CrossrefPubMedGoogle Scholar
  • 34 Rosemurgy AS, Zervos EE, Clark WC. , et al. TIPS versus peritoneovenous shunt in the treatment of medically intractable ascites: a prospective randomized trial. Ann Surg 2004; 239 (06) 883-889 , discussion 889–891
    CrossrefPubMedGoogle Scholar
  • 35 Busuttil RW, Farmer DG, Yersiz H. , et al. Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. Ann Surg 2005; 241 (06) 905-916 , discussion 916–918
    CrossrefPubMedGoogle Scholar